ABSTRACT

HCV INHIBITING SULFONAMIDES

The present invention concerns sulfonamide derivatives having the general formula



and *N*-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs and esters thereof, wherein Q_1 is –S- or –O-; R_1 is hydrogen, C_{1-6}alkyl, hydroxy, amino, halogen, aminoC$_{1-4}$alkyl and mono-or di(C_{1-4}alkyl)amino; R_2 is hydrogen or C_{1-6}alkyl; R_3 is C_{1-6}alkyl, aryl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4}alkyl, or arylC_{1-4}alkyl; R_4 is hydrogen, C_{1-4}alkyloxycarbonyl, carboxyl, optionally mono- or disubstituted aminocarbonyl, mono- or di(C_{1-4}alkyl)aminocarbonyl, C_{3-7}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl or C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from aryl, Het^1, Het^2, C_{3-7}cycloalkyl, C_{1-4}alkyloxy-carbonyl, carboxyl, aminocarbonyl, mono- or di(C_{1-4}alkyl)aminocarbonyl, aminosulfonyl, C_{1-4}alkylS(=O)$_t$, hydroxy, cyano, halogen or amino optionally mono- or di-substituted where the substituents are each independently selected from C_{1-4}alkyl, aryl, arylC_{1-4}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4}alkyl, Het^1, Het^2, Het$^1C_{1-4}$alkyl and Het$^2C_{1-4}$alkyl; Q_2 is a radical of formula



for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV. The present invention also relates to the use of said sulfonamides in pharmaceutical compositions aimed to treat or combat combined HCV and HIV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present sulfonamides with other anti-HCV agents and/or anti-HIV agents.